Evidence map›Paper›PMID 38455401›Full record

ArticleAmerican journal of cancer research2024

CD39

Yuan Feng, Xin Xu, Jiaxin Zhang, Christopher Sanderson, Jun Xia, Zhang Bu, Yili Yang, Peng Yang, Zhiliang Lu

Open access · bronzeAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Targeting CD39 as a Therapeutic for Cancer Immunotherapy.Expert reviews in molecular medicine · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuan FengChina Regional Research Center, International Centre for Genetic Engineering and Biotechnology Taizhou 225300, Jiangsu, P. R. China.
Xin XuChina Regional Research Center, International Centre for Genetic Engineering and Biotechnology Taizhou 225300, Jiangsu, P. R. China.
Jiaxin ZhangChina Regional Research Center, International Centre for Genetic Engineering and Biotechnology Taizhou 225300, Jiangsu, P. R. China.
Christopher SandersonInstitute of Translational Medicine, University of Liverpool Liverpool L69 7ZX, UK.
Jun XiaDepartment of Emergency Medicine, The First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu, P. R. China.
Zhang BuDepartment of Emergency Medicine, The First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu, P. R. China.
Yili YangChina Regional Research Center, International Centre for Genetic Engineering and Biotechnology Taizhou 225300, Jiangsu, P. R. China.
Peng YangDepartment of Emergency Medicine, The First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu, P. R. China.
Zhiliang LuDepartment of Biological Sciences, School of Science, Xi'an Jiaotong-Liverpool University Suzhou 215123, Jiangsu, P. R. China.
Xi’an Jiaotong-Liverpool University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies revealed that CD39 was highly expressed in tumor-specific CD4

Indexed as

CD39colorectal cancerneoantigenPBLsTILs

Identifiers

PMID38455401
PMCPMC10915329
OpenAlexW4394761545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.